Result of phase II clinical trial of herceptin in advanced Chinese breast cancer patients

Yan Sun, Li qing Li, San tai Song, Li gong Xu, Shi ying Yu, Jin wan Wang, Ze fei Jiang, Ji liang Yin, Hui hua Xiong

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

OBJECTIVE: To observe the clinical efficacy and adverse effects of herceptin for advanced Chinese breast cancer patients. METHODS: Thirty-one pathologically proved advanced breast cancer women were treated by herceptin. In the first week, a loading dose 4 mg/kg was administered by intravenous infusion and from the second week, a routine dose of 2 mg/kg was given every week for at least 3 months. RESULTS: There were 2 CR, 6 PR, 7 SD, and 16 PD among 31 patients after treatment by herceptin, the response rate being 25.8%. In factors influencing the prognosis, age and general condition were factors favoring the results, and pathological type, site of metastasis, grade of her-2 over expression and prior treatment were irrelevant to the results. The adverse effects were mild but different from those of the common anticancer drugs. CONCLUSION: Herceptin is effective and well tolerated by the Chinese breast cancer patients.

Original languageEnglish
Pages (from-to)581-583
Number of pages3
JournalZhonghua zhong liu za zhi [Chinese journal of oncology]
Volume25
Issue number6
StatePublished - Nov 2003

Fingerprint

Dive into the research topics of 'Result of phase II clinical trial of herceptin in advanced Chinese breast cancer patients'. Together they form a unique fingerprint.

Cite this